UNRESECTABLE COLON ADENOCARCINOMA
Clinical trials for UNRESECTABLE COLON ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE COLON ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE COLON ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat colorectal cancer: drug duo targets tumor defenses
Disease control OngoingThis study tests a combination of two drugs—SX-682 and nivolumab—in people with a specific type of advanced colorectal cancer (RAS-mutated, MSS) that has spread or can't be removed. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 51…
Matched conditions: UNRESECTABLE COLON ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 05:34 UTC
-
Triple therapy offers new hope for Hard-to-Treat colorectal cancer
Disease control OngoingThis study tests a combination of two targeted drugs (encorafenib and cetuximab) plus an immunotherapy drug (nivolumab) in people with advanced colorectal cancer that has a specific BRAF mutation and is stable (not MSI-high). The goal is to see if this triple therapy can shrink t…
Matched conditions: UNRESECTABLE COLON ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 05:33 UTC
-
New drug cocktail shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingThis study tests whether adding two targeted drugs (LY3214996 and abemaciclib) to the standard drug cetuximab can shrink tumors or slow cancer growth in people with advanced colorectal cancer that no longer responds to cetuximab alone. About 46 adults with metastatic or inoperabl…
Matched conditions: UNRESECTABLE COLON ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Immunotherapy boost may tame tough colorectal cancer
Disease control OngoingThis study is for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E) and has not responded to prior treatment. It compares the usual two-drug therapy (encorafenib and cetuximab) against the same two drugs plus an immunotherapy drug called nivol…
Matched conditions: UNRESECTABLE COLON ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:19 UTC